MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is ...